Most men who start a TRT, GLP-1, or longevity protocol ask the same question after the first few months: when do I actually need to get blood drawn again? The honest answer is that it depends on what you are taking, how long you have been on it, and whether anything about your dose or symptoms has changed, not on a fixed calendar reminder.
This guide walks through the retest cadence recommended by the relevant clinical guidelines for each protocol type, what triggers an earlier-than-scheduled recheck, and who actually reviews your results on a LodeRx protocol.
In this article:
- Why Retest Cadence Matters More Than the First Panel
- TRT Retest Cadence: What Changes at 6 Weeks, 3 Months, and Annually
- GLP-1 Retest Cadence: Metabolic and Safety Panels Across a Dose Titration
- Longevity Protocol Retest Cadence: Quarterly Audits vs Annual Deep Dives
- Comparison Table: Retest Intervals by Protocol Type
- What Triggers an Off-Cycle Retest Regardless of Schedule
- How LodeRx Patients Get Bloodwork Scheduled and Reviewed
- FAQ
Why Retest Cadence Matters More Than the First Panel
A baseline panel does one job: it tells a clinician whether you are a reasonable candidate for a given therapy and establishes a starting point. It does not tell anyone whether the therapy is working or whether it is safe to continue at the current dose months later.
Follow-up labs serve a different purpose. They confirm the body is responding as expected and, just as important, they catch early safety signals before those signals turn into symptoms you would notice on your own.
That is the core reason a single retest cadence does not work across the board. Hormone optimization, GLP-1 titration, and broad longevity screening each run on their own clock, driven by how quickly the relevant markers move and how much risk accumulates between checks.
A normal panel from six months ago does not represent today's physiology, especially after a dose change or the start of a new medication. Bloodwork is a snapshot, not a subscription.
TRT Retest Cadence: What Changes at 6 Weeks, 3 Months, and Annually {#trt-retest-cadence}
The most widely cited guidance for testosterone replacement therapy monitoring comes from the Endocrine Society's 2018 Clinical Practice Guideline (Bhasin et al., Journal of Clinical Endocrinology & Metabolism). It recommends rechecking total testosterone 3 to 6 months after starting therapy or after any dose change, then moving to an annual check once levels are stable.
The same guideline lays out safety monitoring beyond the hormone number itself:
- Hematocrit, checked periodically to screen for erythrocytosis (an increase in red blood cell concentration associated with testosterone therapy)
- PSA (prostate-specific antigen), monitored periodically as part of standard safety follow-up
- Lipid panel, reviewed at intervals alongside the above
A detail that trips people up: a dose adjustment resets the clock. If your weekly testosterone dose changes, that warrants a recheck ahead of your next scheduled annual panel, not a wait until the calendar date arrives. Your EliteCare clinician uses your actual results, not a generic timetable, to decide when the next draw should happen.
GLP-1 Retest Cadence: Metabolic and Safety Panels Across a Dose Titration {#glp-1-retest-cadence}
GLP-1 therapies are typically titrated upward over weeks to months, and monitoring follows that titration rather than a single fixed interval.
FDA prescribing information for semaglutide, the active ingredient in the FDA-approved brand-name medications Ozempic and Wegovy, describes periodic monitoring during dose escalation, including attention to renal function and gastrointestinal tolerability. That monitoring framework is a reasonable reference point regardless of which formulation a patient is using.
On the glycemic side, the American Diabetes Association's 2024 Standards of Care recommends A1C testing roughly every 3 months while a glucose-lowering therapy is being adjusted. Translated into practice, that means:
- A baseline panel before starting, including A1C, fasting glucose, lipids, and kidney function
- A recheck at or near each dose increase, not only at the final maintenance dose
- A broader metabolic recheck roughly every 3 months while titration is active
- A return to a calmer, less frequent cadence once the dose has been stable for a while
Lipid panel, kidney function, and weight trend are reasonable checkpoints at each step up, because they can shift meaningfully before a patient notices any symptom.
Compounded semaglutide disclosure: when a LodeRx patient is prescribed a compounded semaglutide formulation, it is prescribed by a licensed EliteCare clinician and compounded and dispensed by RxAve or another 503A partner pharmacy. Compounded formulations are not FDA-approved; FDA approval applies to the brand-name medications themselves, not to compounded versions of the active ingredient.
Longevity Protocol Retest Cadence: Quarterly Audits vs Annual Deep Dives {#longevity-protocol-retest-cadence}
Longevity-focused panels, think inflammatory markers, lipid particle testing, and fasting insulin, generally live on a slower clock than TRT or GLP-1 monitoring, because there is usually no active titration forcing more frequent checks.
As a general pattern:
- Annual deep dives make sense for broad risk-marker panels when no specific intervention is under active evaluation.
- Quarterly audits make more sense when you are isolating a single variable, such as a new training block, a sleep intervention, or a supplement, against a narrow set of markers tied to that specific change.
A short standalone point worth repeating: testing without a clear question to answer mostly adds cost and noise. Cadence should match the pace of whatever you are actually changing, not a fixed habit carried over from a previous protocol.
Comparison Table: Retest Intervals by Protocol Type
The table below lays out how cadence differs by what is actually being tracked, not by brand or provider.
| Protocol | Primary markers tracked | First recheck | Steady-state cadence | Off-cycle trigger |
|---|---|---|---|---|
| TRT | Total testosterone, hematocrit, PSA, lipids | 3 to 6 months after start or dose change | Annually once stable | Any dose change, new symptoms |
| GLP-1 | A1C, fasting glucose, lipids, renal function, weight trend | At or near each dose increase | Roughly every 3 months during titration | Persistent GI symptoms, dose change |
| Longevity | Inflammatory markers, lipid particles, fasting insulin | Varies by baseline findings | Annually, absent an active intervention | Quarterly if testing a specific variable |
The pattern across all three rows is the same: cadence follows the marker's rate of change and the therapy's risk profile, not a single universal schedule.
What Triggers an Off-Cycle Retest Regardless of Schedule
Scheduled intervals are a floor, not a ceiling. Certain situations call for a recheck before the next calendar date, regardless of protocol:
- New or worsening symptoms, such as fatigue, mood change, or gastrointestinal symptoms, warrant a recheck before the next scheduled date.
- Any dose change, up or down, should be followed by a recheck rather than waiting for the standing interval to arrive.
- A gap of several weeks or more without taking a prescribed medication as directed can make your last panel unrepresentative of your current levels, which matters if a clinician is using that panel to make a decision.
If something about how you feel has changed since your last draw, that is reason enough to ask your EliteCare clinician whether an earlier recheck makes sense. Feeling fine is useful information, but it is not a substitute for a scheduled test.
How LodeRx Patients Get Bloodwork Scheduled and Reviewed
It is worth being direct about who does what here. LodeRx is a marketing brand; it does not review labs, practice medicine, or set your retest cadence. Those clinical decisions, including when you get rechecked and how your dose is adjusted, are made by EliteCare, a network of state-licensed clinicians.
Here is how the pieces fit together for a LodeRx patient:
- Medications are prescribed by a licensed clinician and compounded and dispensed by RxAve or another 503A partner pharmacy.
- Intake, scheduling, and result review happen through the Ola Digital Health patient portal.
- LodeRx holds LegitScript Healthcare Merchant Certification (certification 50431222, effective July 30, 2026). LegitScript certification is a healthcare merchant compliance and accreditation certification; it is not FDA approval and not a medical endorsement.
To see how candidacy evaluation works before you ever reach a lab order, review our guide to what to expect from a TRT intake consultation or how GLP-1 dose titration typically proceeds. For a broader look at how longevity screening fits into an overall plan, our longevity protocol overview covers panel selection in more depth.
FAQ
How often should I get bloodwork while on TRT?
The Endocrine Society's 2018 guideline recommends checking testosterone 3 to 6 months after starting therapy or after a dose change, then annually once levels are stable, with periodic hematocrit, PSA, and lipid monitoring. Your EliteCare clinician sets the exact schedule based on your results and any dose adjustments.
Do I need new labs every time my GLP-1 dose increases?
A recheck around each dose increase is reasonable, since FDA prescribing information for semaglutide describes monitoring during titration and the American Diabetes Association recommends A1C testing roughly every 3 months while therapy is being adjusted. Your clinician will tell you which markers matter at each step.
What labs matter most for a longevity protocol?
Common markers include fasting insulin, lipid particles, and inflammatory markers, typically reassessed annually unless a specific intervention is being tested. If you are isolating one variable, like a supplement or training change, a quarterly recheck of a narrow panel can show whether it is working.
Can I skip a scheduled retest if I feel fine?
Feeling fine is useful information, but it does not replace a scheduled recheck, since some safety markers, like hematocrit on TRT, change without obvious symptoms. Talk to your clinician before skipping or delaying a panel, especially after a dose change.
Who reviews my bloodwork results on a LodeRx protocol?
LodeRx is a marketing brand and does not review labs or practice medicine. Results are reviewed by EliteCare state-licensed clinicians, who set your retest cadence and any dose adjustments, while prescriptions are compounded and dispensed by RxAve and other 503A partner pharmacies.
If you are unsure whether your current retest schedule still fits your protocol, the next concrete step is to request an intake review with an EliteCare clinician, who can look at your history and tell you whether an earlier panel makes sense before your next scheduled date.